Gastrointestinal symptoms are the most common manifestations of tirzepatide overdose and may include: Severe nausea and vomiting : Often persistent and more intense than typical side effects, potentially leading to inability to retain fluids or medications Abdominal pain or cramping : May range from mild discomfort to severe pain, typically in the upper abdomen Diarrhea : Can contribute to dehydration and electrolyte imbalances Loss of appetite : Complete aversion to food, extending beyond normal appetite suppression Metabolic disturbances requiring medical attention: Hypoglycemia : Symptoms include trembling, sweating, rapid heartbeat, confusion, dizziness, hunger, irritability, and in severe cases, loss of consciousness or seizures
Those experiencing ongoing digestive symptoms may find that Wegovy's gastrointestinal side effects are more pronounced or difficult to tolerate
Does Category 1 status mean BPC-157 is FDA approved
These SCFAs activate free fatty acid receptors (FFAR2 and FFAR3) on intestinal L-cells, directly stimulating GLP-1 secretion
(1) Not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m2